Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388187 | 0.86 | KDM4E (1.00) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL29059277 | 0.83 | KDM4E (0.76) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL27699005 | 0.81 | MAPT (0.81) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL30523129 | 0.80 | KDM4E (0.67) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL29059305 | 0.80 | KDM4E (0.67) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL17483786 | 0.80 | KMT2A (1.00) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL29059323 | 0.80 | KDM4E (0.66) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL13336468 | 0.79 | KDM4E (0.72) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL3384928 | 0.78 | KDM4E (0.71) | KMT2AMEN1KDM4EMAPTHTT | |
| SCHEMBL13561093 | 0.78 | MAPT (1.00) | KMT2AMEN1KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009020267-A1 | COMPETITORS OF MICROPHTHALMIA TRANSCRIPTION FACTOR AND THE COSMETIC COMPOSITION COMPRISING THEREOF | INHA-INDUSTRY PARTNERSHIP INSTITUTE (KR) | 2009-02-12 | — | — | WO | claimed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2009020267-A1 | COMPETITORS OF MICROPHTHALMIA TRANSCRIPTION FACTOR AND THE COSMETIC COMPOSITION COMPRISING THEREOF | INHA-INDUSTRY PARTNERSHIP INSTITUTE (KR) | 2009-02-12 | — | — | WO | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | KMT2A 1259/4885MEN1 2314/4885KDM4E 3141/4885 |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | KMT2A 2287/4885MEN1 1613/4885KDM4E 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.